Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06406465
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:29:02.934850+00:00
Published At
2026-04-24T00:00:00+00:00
Record Updated At
2026-04-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Carcinoma, Neuroendocrine", "Tumor, Neuroendocrine", "Tumors, Neuroendocrine", "Neuroendocrine; Carcinoma", "Small Cell; Receptors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-24"
protocolSection.identificationModule.nctId
"NCT06406465"
protocolSection.identificationModule.officialTitle
"A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Carcinoma, Neuroendocrine (protocolSection.conditionsModule.conditions)
  • Tumor, Neuroendocrine (protocolSection.conditionsModule.conditions)
  • Tumors, Neuroendocrine (protocolSection.conditionsModule.conditions)
  • Neuroendocrine; Carcinoma (protocolSection.conditionsModule.conditions)
  • Small Cell; Receptors (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.